Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Bruker Introduces Novel AVANCE III HD NMR Spectrometer

Published: Monday, July 09, 2012
Last Updated: Monday, July 09, 2012
Bookmark and Share
The new AVANCE III HD is the Ultimate NMR platform for life science and materials research, as well as a robust, automated and easy-to-use analysis system for pharma/biotech, chemistry, metabolomics, nutritional science and molecular diagnostics research.

At the Experimental Nuclear Magnetic Resonance Conference (ENC) 2012, Bruker has introduced the novel AVANCE III HD NMR spectrometer.

Thanks to its new digital RF synthesizer, further enhanced receiver electronics, redesigned preamplifiers, extended Digital Lock™ and SmartVT™ capabilities, Bruker now has further enhanced the most sensitive and most accurate, highest performance NMR spectrometer on the market, bringing High Definition (HD) technology to AVANCE NMR users.

The AVANCE III HD spectrometer benefits from a next-generation RF synthesizer with significantly increased digital integration, incorporating a lower phase noise local oscillator (LO) and a high speed DA converter running at 960 MHz.

This enables extended digital RF power settings up to NMR frequencies of 1.2 GHz.

Together with the new high dynamic range and high sensitivity preamplifiers, the AVANCE III HD demonstrates improved spectral purity, fully exploits the increased sensitivity of the latest NMR probe technology and enables sensitivity improvements of up to 30% for the most demanding applications.

These include experiments on bio-molecular samples in buffers or detergents, metabolic beverage analysis for food safety and quality, and trace analysis such as impurity detection in drugs and other pharmaceutical compounds.

With the new AVANCE III HD preamplifiers and the new GaAs FET-based broad-band technology, solid-state NMR applications in particular will directly benefit from up to a 20% increase in sensitivity on 13C and other X nuclei.

A novel impedance matching technology ensures solids spectra with excellent symmetry, and the active, fast high power transmit/receive switch guarantees maximum linearity even at the lowest power levels.

The AVANCE III HD now provides solid-state NMR researchers with access to fully broad-banded capacities and easier daily routine operation without the need for manual interaction.

A touch-screen display enables high-definition tuning and matching of the system and monitoring of the probe status.

With the revolutionary NMR Thermometer™ for the first time, the measurement of the exact internal sample temperature by NMR itself is possible.

This is achieved fully automatically through the measurement of the chemical shift difference between two deuterium resonances, rather than relying on inaccurate external thermocouples.

While one deuterium signal is used for field stabilization, the chemical shift difference to the second signal is used together with the SmartVT™ to both measure and maintain a constant temperature within the sample.

Based on the measurement of the actual sample temperature, the NMR Thermometer™ now offers the possibility of up to 50% times faster on-line regulation of sample temperature, more efficient compensation for heating effects caused by RF pulse sequences, or by sample spinning in MAS experiments.

This results in an immediate improvement in the accuracy and precision of the acquired signal frequencies by up to a factor 5, delivering improved accuracy in the assignment of resonances, especially in solid-state, and 2D/3D/4D protein and biomolecular NMR applications.

"With our unsurpassed commitment to innovation and to bringing the latest technology to the field of NMR, the new AVANCE III HD spectrometer once again offers enabling R&D innovations and performance breakthroughs from our R&D centers and key customer collaborations to all NMR customers," said Dr. Frank Laukien, Bruker's President and CEO.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bruker MALDI Biotyper™ Receives CFDA Clearance
Company receives clearance from the China Food and Drug Administration to market and sell its IVD MALDI Biotyper System as a medical device in China for the identification of microorganisms isolated from human specimens.
Thursday, June 26, 2014
Bruker Reports 7% Revenue Growth in Q4
Bruker Corporation reported financial results for its fourth quarter and full year ended December 31, 2013.
Wednesday, February 19, 2014
Bruker Granted FDA Clearance to Market the MALDI Biotyper CA System
Bruker able to market MALDI Biotyper CA System in the US for the identification of Gram negative bacterial colonies cultured from human specimens.
Tuesday, November 26, 2013
Novel Approach for Inborn Errors of Metabolism Screening by NMR
Clinical IEM-by-NMR screening study in Turkey measures 65 metabolites in urine simultaneously, including 20 endogeneous metabolites and 45 metabolites associated with inborn errors of metabolism.
Wednesday, September 04, 2013
Bruker Announces the Appointment of Thomas Bachmann
Appointment of Mr. Bachmann as President of the Bruker BioSpin Group.
Thursday, August 22, 2013
Bruker Announces Framework Agreement with Duzen
Duzen selects Bruker's MALDI Biotyper for mass spectrometry-based molecular microbial identification.
Wednesday, June 06, 2012
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos